525 related articles for article (PubMed ID: 9354444)
21. Potentiation of BCNU antitumor efficacy by 9-substituted O6-benzylguanines. Effect of metabolism.
Kokkinakis DM; Moschel RC; Pegg AE; Schold SC
Cancer Chemother Pharmacol; 2000; 45(1):69-77. PubMed ID: 10647505
[TBL] [Abstract][Full Text] [Related]
22. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA
Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647
[TBL] [Abstract][Full Text] [Related]
23. O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials.
Keir ST; Dolan ME; Pegg AE; Lawless A; Moschel RC; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 2000; 45(6):437-40. PubMed ID: 10854129
[TBL] [Abstract][Full Text] [Related]
24. Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.
Bacolod MD; Johnson SP; Pegg AE; Dolan ME; Moschel RC; Bullock NS; Fang Q; Colvin OM; Modrich P; Bigner DD; Friedman HS
Mol Cancer Ther; 2004 Sep; 3(9):1127-35. PubMed ID: 15367707
[TBL] [Abstract][Full Text] [Related]
25. Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo.
Marathi UK; Dolan ME; Erickson LC
Biochem Pharmacol; 1994 Nov; 48(11):2127-34. PubMed ID: 7802703
[TBL] [Abstract][Full Text] [Related]
26. Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU.
Schold SC; Kokkinakis DM; Rudy JL; Moschel RC; Pegg AE
Cancer Res; 1996 May; 56(9):2076-81. PubMed ID: 8616853
[TBL] [Abstract][Full Text] [Related]
27. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Liu L; Markowitz S; Gerson SL
Cancer Res; 1996 Dec; 56(23):5375-9. PubMed ID: 8968088
[TBL] [Abstract][Full Text] [Related]
28. Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents.
Kokkinakis DM; Ahmed MM; Delgado R; Fruitwala MM; Mohiuddin M; Albores-Saavedra J
Cancer Res; 1997 Dec; 57(23):5360-8. PubMed ID: 9393761
[TBL] [Abstract][Full Text] [Related]
29. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of BCNU anticancer activity by O6-benzylguanine: a study in vitro and in vivo.
Wan Y; Wu D; Gao H; Lu H
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):69-75. PubMed ID: 10905510
[TBL] [Abstract][Full Text] [Related]
31. Depletion of O6-methylguanine-DNA methyltransferase and potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea antitumor activity by O6-benzylguanine in vitro.
Chen JM; Zhang YP; Moschel RC; Ikenaga M
Carcinogenesis; 1993 May; 14(5):1057-60. PubMed ID: 8504466
[TBL] [Abstract][Full Text] [Related]
32. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
Hansen RJ; Nagasubramanian R; Delaney SM; Cherian MM; Lin S; Kogan SC; Dolan ME
J Pharmacol Exp Ther; 2005 Dec; 315(3):1247-55. PubMed ID: 16126841
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
Friedman HS; Dolan ME; Moschel RC; Pegg AE; Felker GM; Rich J; Bigner DD; Schold SC
J Natl Cancer Inst; 1992 Dec; 84(24):1926-31. PubMed ID: 1334154
[TBL] [Abstract][Full Text] [Related]
34. Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines.
Bobola MS; Berger MS; Silber JR
Mol Carcinog; 1995 Jun; 13(2):81-8. PubMed ID: 7605583
[TBL] [Abstract][Full Text] [Related]
35. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Wedge SR; Newlands ES
Br J Cancer; 1996 May; 73(9):1049-52. PubMed ID: 8624262
[TBL] [Abstract][Full Text] [Related]
36. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
[TBL] [Abstract][Full Text] [Related]
37. Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter.
Chen ZP; Pan J; Huang Q; Sun ZF; Zhou LY; Wang AD
J Neurooncol; 2001 Jan; 51(1):19-24. PubMed ID: 11349876
[TBL] [Abstract][Full Text] [Related]
38. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
[TBL] [Abstract][Full Text] [Related]
39. Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea.
Reese JS; KoƧ ON; Lee KM; Liu L; Allay JA; Phillips WP; Gerson SL
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14088-93. PubMed ID: 8943065
[TBL] [Abstract][Full Text] [Related]
40. [Mutation of human O6-alkylguanine-DNA alkyltransferase confers resistance to O6-benzylguanine].
Wan Y; Wu D; Gao H
Zhonghua Zhong Liu Za Zhi; 2000 Jul; 22(4):290-3. PubMed ID: 11778552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]